Talzenna (talazoparib; Pfizer) is a small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP). PARP inhibitors block the activity of PARP, an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events, by directly blocking enzymatic activity, or by causing PARP to accumulate on DNA (PARP trapping), which results in DNA replication inhibition and cell death.
Originally developed by Merck KGaA, Rebif was first launched in the EU in 1998, followed by launch in the US in March 2002.
Rytary (Impax Laboratories) is a novel oral capsule formulation of carbidopa and levodopa that contains both an immediate-release and a sustained-release levodopa component.
Tasigna (nilotinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor. In Philadelphia chromosome-positive chronic myeloid leukemia, the BCR-ABL protein activates a number of cell cycle-controlling proteins and enzymes, speeding up cell division.
Opdivo is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T cells.
PharmaVitae explores Alexion’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
Gazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) is a third-generation, type II glycoengineered, humanized anti-CD20 monoclonal antibody (MAb) that recognizes the type II epitope of the CD20 antigen.
This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, surgical procedure volumes, competitors, and opportunities in the U.S. General and Pelvic Endoscopic Surgery Products Market.
An oral antiplatelet agent, Effient is a pro-drug which is converted to its active metabolite after metabolism by cytochrome P450 enzymes.
Neurointerventional radiology/surgery, or neurovascular intervention, is a relatively new medical specialty employing minimally invasive endovascular techniques to treat vascular diseases of the brain.
This interview covers the current treatment of multiple myeloma in the UK, and the main areas of unmet need.
NovoSeven is a recombinant factor VIIa (rfVIIa) product marketed by Novo Nordisk.
Developed by Genentech, Pulmozyme is a recombinant form of human deoxyribonuclease I produced by genetically engineered Chinese hamster ovary cells
Invanz (ertapenem; Merck & Co) is a carbapenem antibacterial agent that inhibits bacterial cell wall synthesis through binding to penicillin-binding proteins. The drug inhibits the crosslinking of…
Faced with pressure from stakeholders – particularly patients – governments, regulators, and some countries have introduced new options and/or processes to speed up access to medicines. This includes access before marketing authorization, and speeding up the marketing authorization, or less often, the health technology assessment processes.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!